Skip to Content

Case Overview

Status:Status:Investigating
Company Name:Company Name:Alnylam Pharmaceuticals, Inc.
Ticker:Ticker:ALNY
Related Attorneys:Lead Attorneys:Thomas W. Elrod
Related Practices:Related Practices:Securities
On July 30, 2026, Alnylam announced second quarter 2026 financial results. Among other things, the Company reported it has “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” As a result, the Company lowered its total projected TTR net product revenues by approximately $200 million.
 
On this news, shares of Alnylam fell $81.14 per share, or approximately 28%, to close at on $205.48 per share July 30, 2026.

Contact Us About This Case

You may share a link to this page on any of the sites listed below or send link via email: